Oral Drug Delivery
Oral dosing is preferred by both patients and providers because it is less invasive than injectables and leads to higher patient adherence. As the range of pharmaceutical products expands to include peptides, proteins, biopolymer, and macromolecular drugs, many compounds are poorly bioavailable when administered orally and often fail to be therapeutically effective. We have developed hierarchical nanoengineered microparticles, microdevices, and monodispersed polymeric particles to address these challenges and ensure that sensitive cargos are protected against degradation in the GI tract, and those therapeutics are delivered at the site where they will be the most effective. We are also interested in understanding how structural cues can influence bioadhesion and drug permeability at the epithelial interface.
Recent Publications: Nemeth CL, Lykins WR, et al. (2019) Pharm Res
Future Work: Assessing bioactivity of loaded protein and tracking device transit in vivo
Point(s) of Contact: Eva Hansen, Will Lykins